205 related articles for article (PubMed ID: 25373736)
1. Mastl kinase, a promising therapeutic target, promotes cancer recurrence.
Wang L; Luong VQ; Giannini PJ; Peng A
Oncotarget; 2014 Nov; 5(22):11479-89. PubMed ID: 25373736
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of Microtubule Associated Serine/threonine Kinase Like Expression Inhibits Gastric Cancer Cell Growth and Induces Apoptosis by Activation of ERK1/2 and Inactivation of NF-κB Signaling.
An CX; Xie SP; Li HL; Hu YH; Niu R; Zhang LJ; Jiang Y; Li Q; Zhou YN
Curr Med Sci; 2021 Feb; 41(1):108-117. PubMed ID: 33582914
[TBL] [Abstract][Full Text] [Related]
3. MASTL: A novel therapeutic target for Cancer Malignancy.
Fatima I; Singh AB; Dhawan P
Cancer Med; 2020 Sep; 9(17):6322-6329. PubMed ID: 32692487
[TBL] [Abstract][Full Text] [Related]
4. E2F8 confers cisplatin resistance to ER+ breast cancer cells via transcriptionally activating MASTL.
Tian J; Lin Y; Yu J
Biomed Pharmacother; 2017 Aug; 92():919-926. PubMed ID: 28605876
[TBL] [Abstract][Full Text] [Related]
5. MASTL induces Colon Cancer progression and Chemoresistance by promoting Wnt/β-catenin signaling.
Uppada SB; Gowrikumar S; Ahmad R; Kumar B; Szeglin B; Chen X; Smith JJ; Batra SK; Singh AB; Dhawan P
Mol Cancer; 2018 Aug; 17(1):111. PubMed ID: 30068336
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer.
Álvarez-Fernández M; Sanz-Flores M; Sanz-Castillo B; Salazar-Roa M; Partida D; Zapatero-Solana E; Ali HR; Manchado E; Lowe S; VanArsdale T; Shields D; Caldas C; Quintela-Fandino M; Malumbres M
Cell Death Differ; 2018 May; 25(5):828-840. PubMed ID: 29229993
[TBL] [Abstract][Full Text] [Related]
7. MASTL overexpression promotes chromosome instability and metastasis in breast cancer.
Rogers S; McCloy RA; Parker BL; Gallego-Ortega D; Law AMK; Chin VT; Conway JRW; Fey D; Millar EKA; O'Toole S; Deng N; Swarbrick A; Chastain PD; Cesare AJ; Timpson P; Caldon CE; Croucher DR; James DE; Watkins DN; Burgess A
Oncogene; 2018 Aug; 37(33):4518-4533. PubMed ID: 29743597
[TBL] [Abstract][Full Text] [Related]
8. MASTL regulates EGFR signaling to impact pancreatic cancer progression.
Fatima I; Barman S; Uppada J; Chauhan S; Rauth S; Rachagani S; Ponnusamy MP; Smith L; Talmon G; Singh AB; Batra SK; Dhawan P
Oncogene; 2021 Sep; 40(38):5691-5704. PubMed ID: 34331012
[TBL] [Abstract][Full Text] [Related]
9. MASTL inhibition promotes mitotic catastrophe through PP2A activation to inhibit cancer growth and radioresistance in breast cancer cells.
Yoon YN; Choe MH; Jung KY; Hwang SG; Oh JS; Kim JS
BMC Cancer; 2018 Jul; 18(1):716. PubMed ID: 29976159
[TBL] [Abstract][Full Text] [Related]
10. Mitosis perturbation by MASTL depletion impairs the viability of thyroid tumor cells.
Cetti E; Di Marco T; Mauro G; Mazzoni M; Lecis D; Minna E; Gioiosa L; Brich S; Pagliardini S; Borrello MG; Pruneri G; Anania MC; Greco A
Cancer Lett; 2019 Feb; 442():362-372. PubMed ID: 30445205
[TBL] [Abstract][Full Text] [Related]
11. AKT Regulates Mitotic Progression of Mammalian Cells by Phosphorylating MASTL, Leading to Protein Phosphatase 2A Inactivation.
Reshi I; Nisa MU; Farooq U; Gillani SQ; Bhat SA; Sarwar Z; Nabi N; Fazili KM; Andrabi S
Mol Cell Biol; 2020 Apr; 40(10):. PubMed ID: 32123010
[TBL] [Abstract][Full Text] [Related]
12. MASTL promotes cell contractility and motility through kinase-independent signaling.
Taskinen ME; Närvä E; Conway JRW; Hinojosa LS; Lilla S; Mai A; De Franceschi N; Elo LL; Grosse R; Zanivan S; Norman JC; Ivaska J
J Cell Biol; 2020 Jun; 219(6):. PubMed ID: 32311005
[TBL] [Abstract][Full Text] [Related]
13. The MASTL-ENSA-PP2A/B55 axis modulates cisplatin resistance in oral squamous cell carcinoma.
Gouttia OG; Zhao J; Li Y; Zwiener MJ; Wang L; Oakley GG; Peng A
Front Cell Dev Biol; 2022; 10():904719. PubMed ID: 36247015
[TBL] [Abstract][Full Text] [Related]
14. Kinase-Independent Functions of MASTL in Cancer: A New Perspective on MASTL Targeting.
Conway JRW; Närvä E; Taskinen ME; Ivaska J
Cells; 2020 Jul; 9(7):. PubMed ID: 32640605
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide siRNA Screen Identifies the Radiosensitizing Effect of Downregulation of MASTL and FOXM1 in NSCLC.
Nagel R; Stigter-van Walsum M; Buijze M; van den Berg J; van der Meulen IH; Hodzic J; Piersma SR; Pham TV; Jiménez CR; van Beusechem VW; Brakenhoff RH
Mol Cancer Ther; 2015 Jun; 14(6):1434-44. PubMed ID: 25808837
[TBL] [Abstract][Full Text] [Related]
16. Targeted inhibition of MASTL kinase activity induces apoptosis in breast cancer.
Misra G; Rajawat J; Pal R; Smith JC; Kumar A
Life Sci; 2023 Dec; 334():122250. PubMed ID: 37931742
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic natural compounds Enzastaurin and Palbociclib inhibit MASTL kinase activity preventing breast cancer cell proliferation.
Polisety A; Misra G; Rajawat J; Katiyar A; Singh H; Bhatt AN
Med Oncol; 2022 May; 39(5):100. PubMed ID: 35599277
[TBL] [Abstract][Full Text] [Related]
18. MASTL(Greatwall) regulates DNA damage responses by coordinating mitotic entry after checkpoint recovery and APC/C activation.
Wong PY; Ma HT; Lee HJ; Poon RY
Sci Rep; 2016 Feb; 6():22230. PubMed ID: 26923777
[TBL] [Abstract][Full Text] [Related]
19. MASTL is a potential poor prognostic indicator in ER+ breast cancer.
Zhuge BZ; Du BR; Meng XL; Zhang YQ
Eur Rev Med Pharmacol Sci; 2017 May; 21(10):2413-2420. PubMed ID: 28617547
[TBL] [Abstract][Full Text] [Related]
20. MASTL is the human orthologue of Greatwall kinase that facilitates mitotic entry, anaphase and cytokinesis.
Voets E; Wolthuis RM
Cell Cycle; 2010 Sep; 9(17):3591-601. PubMed ID: 20818157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
